EGFR and cancer: Patients (n = 1494) with EGFR TKI reimbursements (2011–2020) and data available in the Finnish Cancer Registry with concurrent analgesics purchases (nonsteroidal anti‐inflammatory drugs [NSAID], acetaminophen, weak and strong opioids, strong opioids stratified by immunomodulatory properties) were identified.